Inventor
Jean-Michel Rene Rondeau
Inventor
Rixheim, FR
Overview
Patents· 22 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07KPeptides20%
C12NMicroorganisms or enzymes15%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
C07DHeterocyclic compounds4%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture4%
C07CAcyclic or carbocyclic compounds3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
PatentTitleYear
11,111,293IL-18 binding molecules202111,008,5703' end caps for RNAi agents for use in RNA interference202110,745,473Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules202010,683,349Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders202010,626,172Antibody drug conjugates202010,519,446Organic compounds to treat hepatitis B virus201910,344,084IL-17 antagonistic antibodies201910,227,5883'end caps for RNAi agents for use in RNA interference201910,081,677IL-18 binding molecules201810,005,836Antibody drug conjugates201810,000,561Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules20189,988,627Formats for organic compounds for use in RNA interference20189,938,342Nucleic acid encoding anti-IL-17A antibodies20189,765,140'IL-17 antagonistic antibodies'20179,650,439'Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory'20179,376,489'IL-18 binding molecules'20169,193,788'Anti-IL-17A antibodies and their uses'20158,617,552'IL-17 antibodies'20138,119,131'IL-17 antagonistic antibodies'20128,093,406'Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors'20127,977,323'C2-C5-alkyl-imidazole-bisphosphonates'20117,807,155'IL-17 antagonistic antibodies'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010–2021Patents assigned to NOVARTIS AG (21)· patent assignee history
2010–2021Based in Rixheim, FR· patent location history
2012–2017Patents assigned to DI PADOVA FRANCO E (4)· patent assignee history
2012–2013Patents assigned to RONDEAU JEAN-MICHEL (3)· patent assignee history
2015–2020Patents assigned to HUBER THOMAS (4)· patent assignee history
2015–2021Based in Basel, CH· patent location history
2018–2020Patents assigned to RONDEAU JEAN MICHEL RENE (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| NOVARTIS AG | 21 | 2010–2021 |
| RONDEAU JEAN MICHEL RENEself | 5 | 2018–2020 |
| DI PADOVA FRANCO E | 4 | 2012–2017 |
| HUBER THOMAS | 4 | 2015–2020 |
| RONDEAU JEAN-MICHELself | 3 | 2012–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Rixheim, FR | 14 | 2010–2021 |
| Basel, CH | 8 | 2015–2021 |